Edwards Lifesciences Aktie News

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards....

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, leaving the sector feeling like a missed opportunity.

Alphabet continued to make significant contributions to performance during the quarter. Taiwan Semiconductor Manufacturing also contributed to performance during the quarter. Old Dominion Freight Line contributed to performance as investors rotated into more economically sensitive sectors late in the year. Meta Platforms was a leading detractor from performance during the quarter despite report...

Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company's proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that ...

The U.S. Federal Trade Commission won a ruling on Friday blocking Edwards Lifesciences Corp's acquisition of Jenavalve Technology Inc, court records showed.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug Administration (FDA) approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for ...